Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
Ulrich Pecks, Head of Obstetrics and Maternal Health and Fetal Development at University Hospital Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“In addition to our recent publication on VTE prophylaxis after CS in JPM we are proud of our accepted review in Archives which provides an overview of guidelines for hereditary thrombophilia in pregnancy.
Key points:
- Pregnant women with inherited thrombophilia have a significantly higher risk of venous thromboembolism (VTE), up to approximately 40-fold depending on type and history.
Risk classification:
- Low risk: e.g., heterozygous factor V Leiden or prothrombin mutation
- High risk: e.g., homozygous mutations, combined thrombophilia, severe antithrombin/protein C/S deficiency
Guidelines vary:
International recommendations for thromboprophylaxis differ widely – no universal standard.
Use of prophylaxis (heparin):
Generally recommended for high-risk thrombophilia (during pregnancy and 6 weeks postpartum).
For low-risk, only if additional risk factors or positive family history are present.
Limited evidence:
There is no strong evidence from randomized controlled trials proving that pharmacological prophylaxis significantly reduces VTE risk.
Risk–benefit balance:
Prophylaxis carries risks (e.g., bleeding), and VTE risk may be overestimated – possible overtreatment.
Individualized decision-making:
Management should be case-by-case, considering individual risk profile, history, and patient preference.
Bottom line:
Although VTE risk is increased in pregnant women with thrombophilia, inconsistent guidelines and limited evidence mean that prophylaxis decisions must be individualized.”
Title: Recommendations from guidelines for the prevention of venous thromboembolism in pregnant women with inherited thrombophilia
Authors: Werner Rath, Panagiotis Tsikouras, Ulrich Pecks
Read the Full Article on Archives of Gynecology and Obstetrics.
Stay updated on all scientific advances with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF